Volume 5, Issue 3
Editorialp. 231–233
Incidental findings in clinical research: the case of the known unknown
Author(s): Blair Henry
Opinion Articlep. 235–238
Clinical trials: beyond efficiency-why are we flying blind?
Author(s): Greg Koski, Matthew Whalen
Commentaryp. 239–246
Quality data collection: paying attention to the details
Author(s): Julie Pepe, Christina Jackson
Drug Evaluationp. 247–255
Vedolizumab for the treatment of inflammatory bowel diseases
Author(s): Reena Khanna & Brian G Feagan
Drug Evaluationp. 257-265
Updated review of nilotinib as frontline treament for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
Author(s): Massimo Breccia, Matteo Molica & Giulina Alimena
Drug Evaluationp. 267–285
Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence
Author(s): Philip Ames & Anat Galor
Clinical Trail Perspectivep. 287–296
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Author(s): Gregory Cheng
Clinical Trail Perspectivep. 297–309
Alzheimers disease clinical trials: past failures and future opportunities
Author(s): Roy Yaari & Ann Hake
Clinical Trail Methodologyp. 311–320
Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation
Author(s): Michael G Kenward
Clinical Trail Outcomesp. 321–335
Immune tolerance induction in hemophilia
Author(s): Maria Elisa Mancuso & Antonino Cannavo
Clinical Trail Outcomesp. 337–350
Treatment of polycystic ovary syndrome: recent trial results
Author(s): Mohd Ashraf Ganie, Semanti Chakraborty & Hammadur Rehman
